SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 14D9 - Solicitation, recommendation statements:
SEC Accession No. 0001193125-20-323922
Filing Date
2020-12-22
Accepted
2020-12-22 08:33:29
Documents
3

Document Format Files

Seq Description Document Type Size
1 SC 14D9 d21517dsc14d9.htm SC 14D9 462022
2 GRAPHIC g21517g41y92.jpg GRAPHIC 29683
3 GRAPHIC g21517g54l80.jpg GRAPHIC 57585
  Complete submission text file 0001193125-20-323922.txt   578489
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Filed by) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Subject) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9 | Act: 34 | File No.: 005-91049 | Film No.: 201406116
SIC: 2836 Biological Products, (No Diagnostic Substances)